ClinicalTrials.gg
RecruitingNCT07095192SCALE POCTUpdated Jul 31, 2025

Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada

An observational study in HCV and HEPATITIS C VIRUS CHRONIC INFECTION, sponsored by McGill University. Recruiting at 12 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by McGill University · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Communicable Diseases with a site in Canada — 7 open to participants now, 8 under way, 2 of them phase 3. Communicable Diseases · Canada.

Started
2025
with 1 other
Observational
8 of 34
2 open now
Registered
32nd of 34
by date

Among the 34 studies in Communicable Diseases with a site in Canada, this one is one of 2 that started in 2025, is one of 8 observational ones, and was the 32nd registered.

Communicable Diseases

628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

7 of the 34 studies in Communicable Diseases with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Communicable Diseases with a site in Canada, or all of them as a file.
02

Study summary

The SCALE-POCT study is a national initiative designed to provide robust evidence for scaling up point-of-care hepatitis C testing for key populations. The study seeks to map current hepatitis C clinical processes, identify barriers and facilitators to implementation, and co-design practical tools and strategies in partnership with stakeholders.

A major obstacle to hepatitis C elimination and increasing treatment uptake is the current multi-step diagnostic process, which leads to loss to follow-up and treatment delays, particularly among high-risk groups such as people who inject drugs. Point of-care hepatitis C antibody tests (results: 5-20 mins) and RNA tests (results: 60 mins), could enable single-visit diagnosis, reducing loss to follow-up. However, integrating these tests into key settings presents challenges. The overarching goal of this study is to generate evidence to inform the scale-up point-of-care hepatitis C testing and treatment in key settings in Canada. This study is observational in nature and does not involve the direct implementation of point-of-care hepatitis C testing. Instead, it aims to understand the contextual, procedural, and operational factors that would support its successful adoption and sustainability. By examining existing care models and engaging with key stakeholders, the study seeks to build a foundation for future implementation efforts. Specific objectives include:

  1. Map current hepatitis C care processes and explore how point-of-care testing could fit into these models;
  2. Identify barriers and facilitators to implementing point-of-care hepatitis C testing across settings and provinces;
  3. Co-design tools and strategies (such as training guides, standard procedures) to support point-of-care testing;
  4. Assess feasibility, acceptability, and costs of the co-designed tools and strategies.
Read the detailed description

Hepatitis C virus (HCV) infection is a major public health threat in Canada (\~204,000 people living with HCV in 2019. HCV therapies with cure >95% are one of the greatest medical advances in decades and have led the WHO to set a goal to eliminate HCV by 2030. In Canada, achieving elimination will require significant increases in diagnoses and treatment . A major barrier to increasing uptake of HCV testing/treatment is that the current diagnostic pathway requires multiple visits (an HCV antibody test to confirm exposure, an HCV RNA test to confirm current infection, and one or more assessments to start treatment) leading to loss to follow-up and delays in treatment. This is amplified in populations with the highest HCV burden, including people who inject drugs (85% of new infections; 46.1% prevalence) and those in prison (10.7% prevalence). People who inject drugs face barriers to accessing HCV care including stigma/discrimination (leading to avoidance of healthcare), inadequate health service access, and poor venous access (making blood collection for testing difficult), whereas people in prison are often released prior to their antibody or RNA result (2, 4, 5). There is an urgent need to leverage innovations to streamline the diagnostic pathway and enhance access to testing/treatment.

The introduction of finger-stick tests capable of detecting HCV antibodies (results: 5-20 minutes) and HCV RNA (results: 60 minutes) at the point-of-care has revolutionized the clinical approach to HCV. These point-of-care tests enable diagnosis and treatment in a single visit, increase testing acceptability, and reduce loss to follow-up. Research by our team has demonstrated excellent technical accuracy and clinical utility of these tests, with pilot studies showing high treatment uptake compared to standard diagnostic approaches, informing recommendation in the 2022 WHO Guidelines and their forthcoming approval by Health Canada. Our team has developed a program for the implementation of point-of-care HCV testing in Australia, resulting in rapid national scale-up across 90 sites, with 20,000 tests and >1,500 people treated (79% treatment uptake; 93% in prisons).

Point-of-care HCV antibody and RNA testing is a 'game-changing' solution to address a critical gap in care and increase equity in healthcare access, particularly for marginalized groups, as we seek to achieve our national elimination targets. The impact of point-of-care testing will be greatest in high HCV prevalence settings (those caring for people who inject drugs), such as needle and syringe programs, drug treatment, prisons, and outreach settings. However, implementation challenges persist, including quality assurance and integration of point-of-care tests into diverse laboratory/public health surveillance frameworks. A systematic, implementation science-based approach is essential to comprehensively identify factors that will limit or enable point-of-care HCV testing within the Canadian context. This is critical for developing specific implementation strategies that address barriers and amplify facilitators to point-of-care testing, and informing changes to health service delivery, guidelines, and provincial and national strategies.

03

Conditions studied

  • HCV
  • HEPATITIS C VIRUS CHRONIC INFECTION

Browse trials for

Keywords

  • HCV
  • Hepatitis C Virus Chronic Infection
  • Rapid point-of-care testing
  • Implementation science
  • Knowledge translation
  • Marginalized populations
  • Infectious diseases
  • Barriers and facilitators
  • Implementation strategies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults at risk of HCV (current/past injecting drug use, current/previous incarceration, HIV, having a tattoo/piercing in an unregulated environment).

Providers (e.g., physicians, nurses, harm reduction workers, street workers) and managers who work with those at risk of HCV, involved in or supervising the delivery of HCV-related services.

Decision-makers: People who hold a position in local, provincial, or national government, health authority, or another organization that influences HCV testing and treatment policies and be able to provide insights into the strategic planning and funding for HCV care.

Laboratory and quality assurance stakeholders: People who provide laboratory services, quality assurance, or regulatory oversight of point-of-care testing at the provincial, national, or organizational level.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged ≥18 years who have a risk factor for acquisition or are attending a site that provides services to people with an HCV acquisition risk.
  • Service providers and managers who are currently employed at a site providing HCV-related services, involved in or supervising the delivery of HCV-related services.
  • Policymaker must hold a position in local, provincial, or national government or a health authority that influences HCV testing/treatment policies and be able to provide insights into the strategic planning and funding for HCV care.
  • Laboratory and quality assurance stakeholders must hold a role in laboratory services, quality assurance, or regulatory oversight of point-of-care testing at the provincial, national, or organizational level.

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years old
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes

Groups and cohorts

  • Consumers

    Individuals aged ≥18 years who have a risk factor for HCV acquisition or are attending a site that provides services to people with an HCV acquisition risk

    Other: Preimplementation of HCV Point of care testing

  • Provider and manager

    Participants must be currently employed at one of the research sites and involved in or supervising the delivery of HCV-related services.

    Other: Preimplementation of HCV Point of care testing

  • Decision-maker

    Participants must hold a position in local, provincial, or national government, health authority or another organization that influences HCV testing and treatment policies and be able to provide insights into the strategic planning and funding for HCV care.

    Other: Preimplementation of HCV Point of care testing

  • Laboratory and quality assurance stakeholder

    Participants must hold a role in laboratory services, quality assurance, or regulatory oversight of point-of-care testing at the provincial, national, or organizational level.

    Other: Preimplementation of HCV Point of care testing

Interventions

  • OtherPreimplementation of HCV Point of care testing

    Exploring the pre-implementation of HCV Point of care antibody and RNA tests

06

What researchers measure

Primary outcomes

  1. Measure Barriers and facilitators based on the CFIR Constructs

    Using the ERIC Taxonomy and the CFIR-ERIC Matching Tool, we will link identified barriers and facilitators to evidence-based implementation strategies. The ERIC Taxonomy includes 73 strategies across 9 clusters, such as training stakeholders, supporting clinicians, engaging consumers, and changing infrastructure. This step will produce a matrix that maps each barrier and facilitator to one or more relevant strategies.

    Time frame: 1 year

  2. Acceptability and Feasibility of Point-of-Care Testing Strategies (Provider/Manager Survey, Section 2)

    The questionnaire adapts the Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM) to assess acceptability and feasibility. Each strategy is evaluated with 8 Likert-scale questions (1-5). Data will be aggregated as mean scores, with higher scores (minimum score: 8, maximum score: 40) indicating greater perceived acceptability/feasibility.

    Time frame: 1 year

  3. Acceptability and Feasibility of Point-of-Care Testing Strategies (Provider/Manager Survey, Section 3)

    The questionnaire adapts the Organizational Readiness for Implementing Change (ORIC) tool to assess feasibility by evaluating if the organization has the commitment and confidence in its ability to implement change. Feasability is assessed through with 12 Likert-scale questions (1-5, minimum score: 12, maximum score: 60)

    Time frame: 1 year

  4. Sustainability of Point-of-Care Testing Strategies using the Time-driven activity-based costing (TDABC)

    Time-driven activity-based costing methodology will guide assessment of costs incurred by health resource use during the patient care cycle to determine the sustainability of the point-of-care testing. This will be done by: 1) determining the frequency, capacity, and average duration of each implementation action by actors, as well as actors' total time spent on each action; 2) determine the price per hour of each actor; 3) determine non-personnel, fixed resources, and their associated expenses; 4) creation and use of a TDABC resource costing matrix to blueprint site-specific implementation processes and calculate total costs;

    Time frame: 1 year

07

Study locations

2 of 12 sites recruiting
  • Anonyme L'Unite D'Intervention
    Montreal, Quebec H1N 1W2, Canada
    Recruiting
    • Renee Logan · Contactrenee.logan@camh.ca · 416-535-8501
    • Mia PhD, NP-PHC, RN, PhD · Principal investigator
  • McGill University
    Montreal, Quebec H3S 1L8, Canada
    Active, not recruiting

    Not enrolling at this site.

  • Indigenous Health Centre of Tiohtià:ke
    Montreal, Quebec, Canada
    Not yet recruiting
    • Carrie Martin, BA, BSW, PhD · Contactcarrie@ihct.ca · 514-482-8557
    • Guillaume Fontaine, RN, PhD · Principal investigator
  • L'Anonyme
    Montreal, Quebec, Canada
    Recruiting
    • Nina Micaleff · Contactnmicaleff@anonyme.ca · 514-842-1488
    • Guillaume Fontaine, RN, PhD · Principal investigator
  • Centre de réadaptation en dépendance de Québec (CRDQ)
    Québec, Quebec, Canada
    Not yet recruiting
  • Medicins du Monde
    Montreal, Canada
    Not yet recruiting
  • Okanagan prison
    Okanagan, Canada
    Not yet recruiting
  • SABSA Cooperative
    Québec, Canada
    Not yet recruiting
  • Sioux Lookout First Nation Health Authority
    Sioux Lookout, Canada
    Not yet recruiting
    • · Contactprivacy@slfnha.com · (807) 737-5182
    • Mia Biondi, PhD, NP-PHC · Principal investigator
  • Ontario - Provincial correction
    Toronto, Canada
    Not yet recruiting
    • Lori Kiefer · Contactlori.kiefer@ontario.ca · 647-302-9916
    • Mia Biondi, PhD, NP-PHC · Principal investigator
  • Rapid Access Addiction Clinic St Paul's Hospital
    Vancouver, Canada
    Not yet recruiting
    • Julia MacIsaac, MD, MPH, ABIM, FRCPC · Contactdrmacisaacmd@gmail.com · 604-806-8867
    • Sofia Bartlett, PhD · Principal investigator
  • Maamwesying North Shore Community Health Services
    Wawa, Canada
    Not yet recruiting
    • Richard Sans Cartier, NP · Contactprivacy@nmninoeyaa.ca · 705-844-2021
    • Mia Biondi, PhD, NP-PHC · Principal investigator
08

References and documents

Publications

  • Mooney M, Weight C, Biondi MJ, Grebely J, Kronfli N, Barnett T, Bruneau J, Dunn K, Elakpa DN, Etherington C, Greenaway C, Martel-Laferriere V, Mendlowitz A, Taylor N, Fontaine G. Scaling up point-of-care hepatitis C testing in Canada: protocol for a multilevel implementation science study of clinical processes, barriers, facilitators and implementation strategies (SCALE-POCT study). Implement Sci Commun. 2025 Dec 18;7(1):10. doi: 10.1186/s43058-025-00837-3. PubMed 41408357 ↗

Individual participant data

Plan to share: No — We won't share IPD, we will share aggregated and analyzed data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jun 2027, 25 months after the start.

Of 128 non-industry observational studies under Communicable Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 77. This study's planned 25 months is below that.

Counting every sponsor, half of 142 studies reached it within 37 months; a quarter within 17 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 31, 2025
StartActual
May 20, 2025
Primary completionEst.
Jun 20, 2027
CompletionEst.
Sep 20, 2028
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07095192
Lead sponsor
McGill University
Collaborators
The University of New South Wales, Canadian Institutes of Health Research (CIHR), Jewish General Hospital, University of British Columbia, British Columbia Centre for Disease Control, University of Toronto, York University, Ottawa Hospital Research Institute, University of Ottawa, McGill University Health Centre/Research Institute of the McGill University Health Centre, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Lady Davis Institute, International Network on Health and Hepatitis in Substance Users, Public Health Agency of Canada (PHAC), Canadian Association of People who Use Drugs, Action Hepatitis Canada, Canadian Liver Foundation, CATIE, Canadian Network on Hepatitis C
Responsible party
Guillaume Fontaine (Assistant Professor, McGill University) — Principal investigator
First posted
Jul 31, 2025
Start date
May 20, 2025
Primary completion
Jun 20, 2027 (estimated)
Completion
Sep 20, 2028 (estimated)
Last update
Jul 31, 2025

Study contacts

Meagan Mooney, RN, MA, BSc
Contact
meagan.mooney@mail.mcgill.ca
514-994-9298
Charlene Weight, MSc, BSc
Contact
charlene.weight@mail.mcgill.ca
5142340348
Guillaume Fontaine, RN, PhD
principal investigator · McGill University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion